Yoshioka Keiji, Kawasaki Tatsuya
Diabetes and Endocrinology, Yoshioka Diabetes Clinic, Osaka, JPN.
Cardiology, Matsushita Memorial Hospital, Moriguchi, JPN.
Cureus. 2025 Aug 13;17(8):e90018. doi: 10.7759/cureus.90018. eCollection 2025 Aug.
Ophthalmic beta-blocker carteolol can rarely cause cardiovascular effects such as bradycardia, heart block, and hypotension. We report a case of carteolol eye drops induced atrioventricular (AV) block. A 76-year-old man with type 2 diabetes developed exercise-induced second-degree AV block, which improved after discontinuing carteolol eye drops in the unilateral eye. Six months later, third-degree AV block recurred due to inadvertent reuse of carteolol eye drops in bilateral eyes despite its prohibition. A seven-day patch electrocardiogram (ECG) monitor showed AV conduction returned to a 1:1 ratio after discontinuation of eye drops. The pacemaker implantation was deferred, and he is currently under close follow-up. Depending on the amount administered to a unilateral eye or bilateral eyes, topical carteolol eye drops can cause second- or third-degree AV block.
眼科β受体阻滞剂卡替洛尔极少引起心动过缓、心脏传导阻滞和低血压等心血管效应。我们报告一例卡替洛尔滴眼液诱发房室传导阻滞的病例。一名76岁的2型糖尿病男性出现运动诱发的二度房室传导阻滞,单侧眼停用卡替洛尔滴眼液后病情改善。六个月后,尽管已被禁止,但因双侧眼不慎再次使用卡替洛尔滴眼液,三度房室传导阻滞复发。七天的动态心电图监测显示,停用滴眼液后房室传导恢复为1:1比例。起搏器植入被推迟,他目前正在密切随访中。根据单侧眼或双侧眼的用药量,局部使用卡替洛尔滴眼液可导致二度或三度房室传导阻滞。